Kenya Kozawa, MD
Internal Medicine · Sweetwater, TNNPI 1568460525
Payments from drug & device makers
Across 1,299 payments — averaging $66.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$41K
- AbbVie$28K
- Boston Scientific$3K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
- AstraZeneca$1K
- Novo Nordisk$1K
- plus $10K from 54 others
Across 1 payment — averaging $1300.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1K
What the payments were for
- Speaking & faculty fees$53,61062%
- Travel & lodging$9,47111%
- Food & beverage$22,89627%
- Education$810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epclusa$39,401
- Mavyret$21,490
- EXALT Model D$1,936
- SPYGLASS$601
- STELARA$255
- TOUJEO$185
- Minimed 770G System$166
- Indigo System$152
- AUSTEDO$127
- GATTEX$125
- FLOWTRIEVER CATHETER, S$123
- CT THROMBECTOMY SYSTEM KIT$123
- Livdelzi$122
- CAPLYTA$116
- NUEDEXTA$114
- MINIMED 780G$110
- AIRSUPRA$110
- LifeVest$104
How this compares
$86,058 in reported general payments places this provider in the 95th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 234 | $158,900 |
| Humira(Cf) PenAdalimumab | 18 | $139,391 |
| Humira PenAdalimumab | 20 | $135,810 |
| LinzessLinaclotide | 148 | $92,260 |
| OzempicSemaglutide | 74 | $78,744 |
| XeljanzTofacitinib Citrate | 11 | $73,708 |
| CreonLipase/Protease/Amylase | 43 | $70,582 |
| EntrestoSacubitril/Valsartan | 55 | $43,158 |
| XareltoRivaroxaban | 61 | $41,572 |
| Nurtec OdtRimegepant Sulfate | 27 | $38,320 |
| MounjaroTirzepatide | 35 | $37,302 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $33,201 |
| VraylarCariprazine Hcl | 20 | $33,189 |
| RybelsusSemaglutide | 18 | $32,567 |
| Enoxaparin Sodium | 52 | $28,715 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Xeljanz, Nurtec Odt, Abrysvo | $865 | $276,409290 claims |
| AbbVieLinzess, Creon, Vraylar | $27,773 | $196,030211 claims |
| Novo NordiskOzempic, Rybelsus | $1,060 | $111,31192 claims |
| Lilly USA, LLCMounjaro, Trulicity | $44 | $51,45146 claims |
| AstraZenecaBrilinta, Farxiga, Symbicort | $1,107 | $45,304104 claims |
| NovartisEntresto | $848 | $43,15855 claims |
| Johnson & JohnsonXarelto | $496 | $41,57261 claims |
| GSKTrelegy Ellipta, Shingrix | $1,051 | $38,94172 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $304 | $32,35153 claims |
| Aimmune Therapeutics, Inc.Zenpep | $114 | $26,70633 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $180 | $20,40814 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $235 | $18,85430 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Sweetwater
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
- Amanda Moore MillerKnoxville$2.3M
- Rick WhilesBristol$1.5M
- John AndersonNashville$1.5M
- David MorinKingsport$1.4M
- John KirbyJefferson City$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.